ENTX Entera Bio Ltd.

3.05
+0.19  (+7%)
Previous Close 2.86
Open 2.9
Price To Book 9.24
Market Cap 37,069,639
Shares 17,864,684
Volume 4,890
Short Ratio
Av. Daily Volume 14,991
Stock charts supplied by TradingView

NewsSee all news

  1. Entera Bio Announces the Completion of $14.3 million Private Placement

    BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (the "Company" or "Entera"), a global innovator in drug delivery platforms, announced today that it increased the size of and

  2. Introducing Investors to Breakthrough Bio-tech Companies: Frost & Sullivan Releases Q3 Equity Research for Investors to Make Informed Decisions

    NEW YORK, Dec. 18, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased and

  3. Entera Announces Closing of Private Placement

    BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (the "Company" or "Entera"), a global innovator in drug delivery platforms, announced today it has closed a private

  4. Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

    BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO.

  5. Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update

    Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients.Conference call

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data from interim (50%) 3-month biomarker endpoint due 2Q 2020.
EB613
Osteoporosis
Phase 2b results presented September 22, 2019.
EB612
Hypoparathyroidism

Latest News

  1. Entera Bio Announces the Completion of $14.3 million Private Placement

    BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (the "Company" or "Entera"), a global innovator in drug delivery platforms, announced today that it increased the size of and

  2. Introducing Investors to Breakthrough Bio-tech Companies: Frost & Sullivan Releases Q3 Equity Research for Investors to Make Informed Decisions

    NEW YORK, Dec. 18, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased and

  3. Entera Announces Closing of Private Placement

    BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (the "Company" or "Entera"), a global innovator in drug delivery platforms, announced today it has closed a private

  4. Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

    BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO.

  5. Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update

    Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients.Conference call

  6. Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019

    BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the

  7. Frost & Sullivan: Major Drug Companies are Securing an Edge by Leveraging the 505(b)(2) Pathway

    NEW YORK, Nov. 5, 2019 /PRNewswire/ -- The discovery and development of new drugs is a long, difficult, and expensive process. A potential new medicine may be rejected at any point in the development process due to

  8. Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions

    NEW YORK, Oct. 7, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased and analysts

  9. Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

    Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual MeetingData suggest favorable pharmacologic and

  10. Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg